This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Daniel Brasnu, MD; Ollivier Laccourreye, MD; Vincent Bassot, MD; Laurent Laccourreye, MD; Philippe Naudo, MD; François-Xavier Roux, MD

Arch Otolaryngol Head Neck Surg. 1996;122(7):765-768.

Abstract
Objective
To review our experience with cisplatin-based neoadjuvant chemotherapy before en bloc resection via a combined neurosurgical and transfacial approach for ethmoid sinus adenocarcinoma reaching and/or invading the skull base.

Design
Case series.

Setting
A tertiary care center and university teaching hospital.

Patients
Twenty-two patients with primary untreated ethmoid sinus adenocarcinoma reaching and/or invading the skull base consecutively treated between 1984 and 1992 with cisplatin-based neoadjuvant chemotherapy and combined neurosurgical and transfacial approach.

Main Outcome Measures
Statistical analysis of survival, local control, nodal recurrence, distant metastasis, and metachronous second primary tumor incidence based on the Kaplan-Meier actuarial method. Univariate analysis was performed to analyze the relationships between various factors, survival, and local recurrence. Clinical response, histological response, toxic effects of chemotherapy, and postoperative course were also reported.

Results
The Kaplan-Meier 3-year survival, local control, nodal recurrence, and distant metastasis estimates were 68.1%, 65.7%, 5.3%, and 10%, respectively. Metachronous second primary tumor was not encountered in our series. Survival was statistically more likely to be reduced in patients with intrasphenoidal tumor extent (P=.04) and local recurrence (P=.01). Local recurrence was statistically more likely in patients with intrasphenoidal tumor extent (P=.002) and no response to cisplatin-based neoadjuvant chemotherapy (P=.03)

Conclusions
The results achieved suggest that cisplatin-based neoadjuvant chemotherapy before combined neurosurgical and transfacial approach should be further investigated for the treatment of ethmoid sinus adenocarcinoma reaching and/or invading the skull base.

Arch Otolaryngol Head Neck Surg. 1996;122:765-768

Author Affiliations
From the Department of Otorhinolaryngology–Head & Neck Surgery, Laënnec Hospital, University Paris (France) V (Drs Brasnu, O. Laccourreye, L. Laccourreye, and Naudo); Department of Oncology, La Pitié-Salpétrière Hospital, University Paris VI, Assistance Publique des Hôpitaux de Paris (Dr Bassot); and Department of Neurosurgery, St-Anne Hospital, University Paris V (Dr Roux). Dr L. Laccourreye is now affiliated with the University of Angers (France).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prediction of TP53 Status for Primary Cisplatin, Fluorouracil, and Leucovorin Chemotherapy in Ethmoid Sinus Intestinal-Type Adenocarcinoma
Licitra et al.
JCO 2004;22:4901-4906.
ABSTRACT | FULL TEXT  

Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer
Licitra et al.
Ann Oncol 2003;14:367-372.
ABSTRACT | FULL TEXT